Jinko offers personalised supportive care to people affected by cancer. The company aims to use the funding to grow its partnerships, boost its visibility among patients and healthcare professionals, and enhance its digital application.
360 Capital, a French venture capital firm investing in early stage, innovative deeptech and digital enterprises across Europe, has led a €2m funding round for Jinko, a French startup which says it is dedicated to enhancing the quality of life of those affected by cancer. AFI Ventures, the impact unit of early-stage digital venture capitalist Ventech, also took part, as well as ten unnamed business angels from the medical, entrepreneurial, insurance, and pharmaceutical sectors.
Inspired by a close friend battling cancer, Faustine Aussedat Bouvier, a former executive at French telecoms giant Orange Group, co-founded Jinko last year alongside Anthony Miossec, a former chief product officer at French workplace firm Comet Meetings.
Jinko offers cancer patients a multidisciplinary care approach, which involves creating a digital personalised plan that connects patients with dietary counselling, psychology, adapted physical activities, osteopathy and other practitioners and medical support.
“The issue of supportive care is still under-addressed today, and we are convinced that the company’s approach will benefit many,” said Clara Cornu, a partner at 360 Capital.
More than eight out of 10 cancer patients experience physical or psychological effects related to their cancer or its treatment. But a number of scientific studies have shown how effective supportive care can be when it comes to reducing mortality, recurrences and side effects, according to Jinko.
Mamadou Dembele, senior associate at AFI Ventures, said he was “impressed” by Jinko’s vision for addressing a market “with limited digital solutions”. Jinko’s holistic approach, which integrates technology with a range of human support services, convinced AFI that it is “the right strategy for this underserved sector”, Dembele said.
Quality of life
Jinko aims to use the funds to grow its partnerships, boost its visibility among patients and healthcare professionals, and enhance its digital application.
“Our goal is to support 1,000 patients in the next 12 months and to continue innovating to provide them with high-quality care, both during and after their cancer treatment,” said co-founder Aussedat Bouvier.
Cancer patients who followed its personalised care plan during a pilot phase reported a 38% average increase in quality of life after three months, according to Jinko.
